Toll-like receptor 7 agonists: chemical feature based pharmacophore identification and molecular docking studies

PLoS One. 2013;8(3):e56514. doi: 10.1371/journal.pone.0056514. Epub 2013 Mar 20.

Abstract

Chemical feature based pharmacophore models were generated for Toll-like receptors 7 (TLR7) agonists using HypoGen algorithm, which is implemented in the Discovery Studio software. Several methods tools used in validation of pharmacophore model were presented. The first hypothesis Hypo1 was considered to be the best pharmacophore model, which consists of four features: one hydrogen bond acceptor, one hydrogen bond donor, and two hydrophobic features. In addition, homology modeling and molecular docking studies were employed to probe the intermolecular interactions between TLR7 and its agonists. The results further confirmed the reliability of the pharmacophore model. The obtained pharmacophore model (Hypo1) was then employed as a query to screen the Traditional Chinese Medicine Database (TCMD) for other potential lead compounds. One hit was identified as a potent TLR7 agonist, which has antiviral activity against hepatitis virus in vitro. Therefore, our current work provides confidence for the utility of the selected chemical feature based pharmacophore model to design novel TLR7 agonists with desired biological activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Algorithms
  • Amino Acid Sequence
  • Computer Simulation
  • Databases, Chemical
  • Drug Design
  • Drugs, Chinese Herbal / chemistry
  • Drugs, Chinese Herbal / pharmacology
  • Humans
  • Hydrogen Bonding
  • Hydrophobic and Hydrophilic Interactions
  • Models, Molecular
  • Molecular Docking Simulation
  • Molecular Sequence Data
  • Structural Homology, Protein
  • Structure-Activity Relationship
  • Toll-Like Receptor 7 / agonists*
  • Toll-Like Receptor 7 / chemistry*
  • Toll-Like Receptor 7 / genetics

Substances

  • Drugs, Chinese Herbal
  • TLR7 protein, human
  • Toll-Like Receptor 7

Grants and funding

This work was supported in part by grants from the National Natural Science Foundation of China (No. 20902068), Doctoral Fund of Ministry of Education of China (No. 20090001120049), Natural Science Foundation of Inner Mongolia Autonomous Region, China (No. 2011BS1201), Project of State Key Laboratory of Natural and Biomimetic Drugs (No. K20110103), and Program for Young Talents of Science and Technology in Universities of Inner Mongolia Autonomous Region, China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.